{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-25-000057","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.709137+00:00","generated_at":"2026-05-16T21:29:59.827965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Connect Biopharma Q3 net loss $17.2M; cash $54.8M; Seabreeze STAT studies on track for 1H26 topline","bullets":["Net loss of $17.2M ($0.31 per share) in Q3 2025 vs $12.9M ($0.23) in Q3 2024; 9-month net loss $40.4M ($0.73) vs $6.7M ($0.12).","License revenue dropped to $16K (Q3) and $64K (9M) from $1.2M and $25.3M in prior-year periods due to upfront and milestone recognition in 2024.","R&D expense increased to $11.1M (Q3) from $9.0M, reflecting initiation of Phase 2 Seabreeze STAT asthma/COPD studies.","Simcere NDA for rademikibart in atopic dermatitis accepted by China NMPA; Connect eligible for up to ~$110M in milestones plus tiered royalties.","Phase 2 Seabreeze STAT studies recruiting participants; topline data expected 1H2026. Cash position of $54.8M expected to fund operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-25-000057","json":"https://secwatch.observer/filing/0001835268-25-000057.json","markdown":"https://secwatch.observer/filing/0001835268-25-000057.md","text":"https://secwatch.observer/filing/0001835268-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000057/0001835268-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000057/cntb-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:29:59.827965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}